LIP
ALNY icon

Liontrust Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Liontrust Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.06M Buy
26,759
+8,541
+47% +$2.58M 0.12% 101
2026
Q1 		$6.03M Sell
18,218
-169
-0.9% -$57.5K 0.1% 114
2025
Q4 		$7.31M Buy
18,387
+6,731
+58% +$2.98M 0.11% 123
2025
Q3 		$5.32M Sell
11,656
-1,113
-9% -$453K 0.08% 129
2025
Q2 		$4.16M Sell
12,769
-6,111
-32% -$1.69M 0.06% 130
2025
Q1 		$5.1M Buy
18,880
+4,857
+35% +$1.25M 0.08% 122
2024
Q4 		$3.3M Buy
14,023
+8,940
+176% +$2.35M 0.05% 131
2024
Q3 		$1.24M Hold
5,083
– – 0.02% 162
2024
Q2 		$1.24M Buy
5,083
+4,933
+3,289% +$779K 0.02% 162
2024
Q1 		$22.4K Sell
150
-431
-74% -$71.9K ﹤0.01% 194
2023
Q4 		$111K Sell
581
-386
-40% -$65.8K ﹤0.01% 192
2023
Q3 		$171K Sell
967
-10,256
-91% -$1.96M ﹤0.01% 189
2023
Q2 		$2.13M Sell
11,223
-22,006
-66% -$4.36M 0.03% 176
2023
Q1 		$6.66M Buy
+33,229
New +$6.98M 0.1% 125
2022
Q4 		– Sell
-28,529
Closed -$5.71M – 187
2022
Q3 		$5.71M Sell
28,529
-5,100
-15% -$973K 0.09% 124
2022
Q2 		$4.9M Buy
+33,629
New +$4.77M 0.07% 149

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Liontrust Investment Partners's ALNY Position: Q2 2026 in Review

Liontrust Investment Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 47% in Q2 2026, buying an estimated $2.58M and bringing the position to 26,759 shares worth $8.06M. The position accounts for 0.12% of the portfolio, ranked #101.

Liontrust Investment Partners first reported a position in ALNY in Q2 2022 and has held it in 16 quarters since. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Liontrust Investment Partners held 26,759 shares of Alnylam Pharmaceuticals worth $8.06M as of Q2 2026.
  • Liontrust Investment Partners bought 8,541 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.58M.
  • Alnylam Pharmaceuticals made up 0.12% of Liontrust Investment Partners's portfolio in Q2 2026, its #101 holding.
  • Liontrust Investment Partners first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Liontrust Investment Partners's 13F filing for Q2 2026, filed 18 Aug 2026.